TrialAmerican journal of hematology2014

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Carlo Gambacorti-Passerini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.